Skip to main content

Branded

  • Bayer's Contour Next Link meter now available with compatible Medtronic insulin pumps

    MORRISTOWN, N.J. — Bayer's latest blood-glucose meter now is available in the United States with Medtronic's compatible integrated diabetes management systems, the companies announced.

  • AstraZeneca, Broad Institute partner on antibiotic, antiviral drugs

    CAMBRIDGE, Mass. — A drug maker and medical research institute will work together to identify new treatments for bacterial and viral infections.

    AstraZeneca and the Broad Institute, owned jointly by Harvard University and MIT, announced Monday that they would collaborate for two years to develop medicines to treat severe infections, saying the identification of high-quality chemicals for the development of new drugs was a significant challenge. The two will use the Broad Institute's collection of 100,000 chemicals known as diversity-oriented synthesis, or DOS compounds.

  • Patients who stop taking insomnia drug continue having sleeping problems, Merck study finds

    WHITEHOUSE STATION, N.J. — A study of an experimental drug for insomnia indicated that patients who stop taking it continue having sleeping problems, according to results of a clinical trial announced Monday.

    Merck released data from a phase-3 trial of suvorexant in which patients who had been taking the drug daily for a year were switched to placebo for a two-month "discontinuation phase." Patients who were switched from the drug to placebo showed sleeping difficulties similar to those who had consistently taken placebo.

  • Takeda: Edarbyclor statistically superior in reducing blood-pressure levels among hypertension patients

    DEERFIELD, Ill. — A Takeda drug designed to treat hypertension was statistically superior to another drug combination in reducing systolic blood pressure among patients in a 10-week, late-stage clinical trial.

  • Study shows rapid growth in cost of physician-dispensed prescriptions versus pharmacies

    CAMBRIDGE, Mass. — While regulations meant to control the prices of drugs dispensed through physician offices for injured workers can keep costs down without limiting access, employers in many states may end up paying more than twice what they would have if the workers had gone to a pharmacy instead, according to a new study.

  • FDA advisory committee recommends approval for Novartis cystic fibrosis drug

    EAST HANOVER, N.J. — A panel of Food and Drug Administration experts is recommending that the agency approve an experimental drug for cystic fibrosis made by Novartis, the Swiss drug maker said.

  • Mylan launches drug reference for mobile devices

    PITTSBURGH — Mylan has launched an application version of the reference guide to its drugs, the generic drug maker said Thursday.

    The company announced what it called the first ever app of its Generic Brand Reference Guide, a free reference for healthcare professionals, patients and pharmacy students that enables the fast identification of brand and generic drugs. The 2012 print edition of the GBR was made available in a pocket-sized format earlier this year.

  • Bayer, Onyx seek approval for gastrointestinal tumor drug

    WAYNE, N.J. — Bayer HealthCare and Onyx Pharmaceuticals are seeking approval for a new drug to treat tumors of the gut, the companies said.

    Bayer and Onyx announced the submission to the Food and Drug Administration of an application seeking approval for regorafenib in patients with gastrointestinal stromal tumors, or GIST. Bayer developed the drug and formed a partnership with Onyx in 2011, whereby Onyx will receive a royalty on future global net sales of the drug in cancer-related indications. Both companies will promote the drug in the United States.

X
This ad will auto-close in 10 seconds